Quantum Machine Learning: Revolutionizing Preclinical Drug Development for Targeted Therapies
Abstract
In the relentless pursuit of groundbreaking advancements in precision medicine, the harmonious amalgamation of quantum computing and machine learning stands as a formidable catalyst in the realm of preclinical drug development. This article endeavors to unveil the seismic shift instigated by Quantum Machine Learning (QML) and its profound ramifications on the inception of precision-targeted therapies. We embark on an exploration of the foundational tenets of quantum computing, its symbiotic integration with machine learning algorithms, and its multifaceted applications in the intricate landscape of preclinical drug discovery.
How strong is the evidence?
Evidence Hub reads this as a preprint, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- In silico toxicology protocols
- QM7-X, a comprehensive dataset of quantum-mechanical properties spanning the chemical space of small organic molecules
- Quantum Informed Machine-Learning Potentials for Molecular Dynamics Simulations of CO2's Chemisorption and Diffusion in Mg-MOF-74
- In-silico strategies in nano-drug design: Bridging nanomaterials and pharmacological applications
- mRNA codon optimization with quantum computers
- The computational power of the human brain
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.